Indoco Remedies Q4 FY26 Preview: Estimates for May 2026

Results event in May 2026

Indoco Remedies (NSE: INDOCO) is expected to report its Q4 FY26 results in May 2026 for the quarter ended March 31, 2026. The company has indicated that a board meeting will consider the financial results for the quarter. For investors, Q4 is closely tracked because it closes the financial year and often sets the baseline for management commentary and the next year’s expectations. The stock has been discussed in multiple pre-result previews in April 2026, and the estimate ranges vary across these notes. Even with differing numbers, the recurring focus points are revenue delivery, profitability, and operating margin trajectory.

Two sets of analyst estimates investors are tracking

Two separate April previews cite different consensus bands for the same quarter. One preview (dated April 23, 2026) puts Q4 FY26 revenue estimates at ₹420-480 crore and PAT at ₹38-50 crore, with an EBITDA margin metric of 12-15%. Another preview (dated April 9, 2026) cites a higher band: revenue of ₹520-560 crore, PAT of ₹50-62 crore, and EBITDA margin of 16-18%. Because both sets are presented as “analyst estimates” in the provided material, investors may see wider-than-usual dispersion going into the print. The market will likely focus on which range better matches reported numbers when results are released.

What the stock snapshot looks like across the previews

The April 23 preview lists a CMP (April 2026) of ₹285, with a 52-week high of ₹420 and a 52-week low of ₹230. The April 9 preview cites the stock at ₹390, against a 52-week high of ₹520, and mentions a 1-year return of -18%. These differences indicate the data is coming from different snapshots and may not be directly comparable. Still, the common takeaway is that the stock has seen meaningful volatility across the year. For results day, price reaction typically depends on how far the numbers land from the market’s working expectations.

Q3 FY26: mixed signals and a difficult base

Q3 FY26 is referenced as the key baseline in the April 9 preview, which states Indoco Remedies reported revenue of ₹490 crore, PAT of ₹44 crore and EBITDA margin of 16.4%. Separately, a Q3 FY26 results note in the provided text reports consolidated revenue of ₹445.4 crore (₹4,454 million) and consolidated EBITDA of ₹25.9 crore (₹259 million). That note also reports a consolidated net loss of ₹29.5 crore (₹295 million), impacted by exceptional items of ₹61.5 crore (₹615 million) linked to New Labour Codes implementation. With these differing Q3 snapshots presented together, readers should treat them as sourced from different summaries and focus on the shared message: revenue growth was reported, operating performance improved in EBITDA terms in one note, but bottom-line outcomes were pressured by exceptional items.

Q4 FY25: weak quarter, losses and revenue decline

The material also includes a reference point for Q4 FY25 performance. Indoco Remedies reported a consolidated net loss of ₹40.4 crore for the quarter ended March 31, 2025. Total revenues were reported at ₹384 crore, down 12.5% year-on-year from ₹439 crore in Q4 FY24. The same note states Q4 FY24 had a net profit of ₹22.7 crore, highlighting the sharp swing to loss in the following year. This history is relevant because Q4 comparisons can amplify headline YoY growth rates when the prior-year base was weak.

Dividend watch: what has been flagged so far

The April 9 preview states the board meeting in May 2026 is expected to approve audited statements and consider a final dividend recommendation. It also mentions an expected final dividend of ₹2-3 per share. Separately, the Q4 FY25 note states the board had proposed a final dividend of ₹0.20 per equity share (face value ₹2) for FY25, subject to shareholder approval. These are not the same periods, but together they show dividend announcements are part of the market’s results-day checklist for the company. Investors typically read dividend quantum as a signal of cash flow comfort, though the actual decision is board-dependent.

Where this fits in the broader Q4 FY26 earnings season

The April 23 preview places Indoco’s results within India’s Q4 FY26 earnings season running through April and May 2026. It also cites an expectation of Nifty 50 aggregate PAT growth of 8-12% YoY. Themes highlighted for the season include margin recovery, capex normalisation, and FY27 guidance. For a mid-cap pharma name, the management commentary around margins and FY27 priorities often matters as much as the reported quarter.

Key metrics to watch on results day

Across the notes, the most repeated operational metric is EBITDA margin, with estimates ranging from 12-15% in one preview and 16-18% in another. Revenue and PAT are the headline numbers investors are told to track, with estimate bands of ₹420-480 crore versus ₹520-560 crore on revenue, and ₹38-50 crore versus ₹50-62 crore on PAT. The April 23 preview also frames outcomes in terms of “beat versus estimates” supporting a re-rating case and a miss increasing downside risk, which reflects how earnings surprises can influence near-term sentiment. Another point raised is the quality of profit, with investors assessing whether PAT is driven by operational improvement or one-time items.

Summary table: what the previews say

Why the Q4 FY26 print matters

Indoco Remedies’ Q4 FY26 results are being positioned as a key earnings event for investors tracking the Pharma / Domestic / Exports theme. The wide estimate range in the provided previews increases the importance of management commentary and the reconciliation between operating performance and reported net profit. The recent history of exceptional items in Q3 FY26 (as cited in one results note) also keeps attention on whether profitability is recurring or impacted by one-offs. The next concrete milestone is the board meeting in May 2026 to consider the quarter’s financial results and related approvals. Until then, market participants are likely to anchor expectations around the stated revenue, PAT, and EBITDA margin bands.